307 related articles for article (PubMed ID: 29572581)
1. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy.
Ayyappan S; William BM
Curr Oncol Rep; 2018 Mar; 20(4):33. PubMed ID: 29572581
[TBL] [Abstract][Full Text] [Related]
2. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Denlinger NM; Epperla N; William BM
Cancer Manag Res; 2018; 10():615-624. PubMed ID: 29628774
[TBL] [Abstract][Full Text] [Related]
3. Effective management strategies for patients with marginal zone lymphoma.
Rosand CB; Valla K; Flowers CR; Koff JL
Future Oncol; 2018 May; 14(12):1213-1222. PubMed ID: 29260925
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
[TBL] [Abstract][Full Text] [Related]
5. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
6. Management of Marginal Zone Lymphoma: A Canadian Perspective.
Peters A; Keating MM; Nikonova A; Doucette S; Prica A
Curr Oncol; 2023 Feb; 30(2):1745-1759. PubMed ID: 36826096
[TBL] [Abstract][Full Text] [Related]
7. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
8. Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA; Feldman TA; McNeill A; Timberg M; Iida H; Goy AH
Expert Rev Hematol; 2019 Dec; 12(12):1011-1022. PubMed ID: 31619091
[No Abstract] [Full Text] [Related]
9. Clinical presentation and management of marginal zone lymphomas.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2005; ():307-13. PubMed ID: 16304396
[TBL] [Abstract][Full Text] [Related]
10. Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.
Cavalloni C; Varettoni M; Rattotti S; Arcaini L
Expert Opin Pharmacother; 2021 Sep; 22(13):1643-1649. PubMed ID: 34120550
[No Abstract] [Full Text] [Related]
11. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
12. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells.
Novak U; Basso K; Pasqualucci L; Dalla-Favera R; Bhagat G
Br J Haematol; 2011 Nov; 155(3):362-5. PubMed ID: 21883140
[TBL] [Abstract][Full Text] [Related]
14. Marginal zone B-cell lymphomas.
Sagaert X; Tousseyn T
Discov Med; 2010 Jul; 10(50):79-86. PubMed ID: 20670602
[TBL] [Abstract][Full Text] [Related]
15. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.
Juárez-Salcedo LM; Castillo JJ
Hematol Oncol Clin North Am; 2019 Aug; 33(4):639-656. PubMed ID: 31229160
[TBL] [Abstract][Full Text] [Related]
16. Marginal-zone lymphoma.
Ferreri AJ; Zucca E
Crit Rev Oncol Hematol; 2007 Sep; 63(3):245-56. PubMed ID: 17583528
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma.
Ikeda JI; Kohara M; Tsuruta Y; Nojima S; Tahara S; Ohshima K; Kurashige M; Wada N; Morii E
Hum Pathol; 2017 Jan; 59():70-79. PubMed ID: 27666766
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.
Rinaldi A; Mian M; Chigrinova E; Arcaini L; Bhagat G; Novak U; Rancoita PM; De Campos CP; Forconi F; Gascoyne RD; Facchetti F; Ponzoni M; Govi S; Ferreri AJ; Mollejo M; Piris MA; Baldini L; Soulier J; Thieblemont C; Canzonieri V; Gattei V; Marasca R; Franceschetti S; Gaidano G; Tucci A; Uccella S; Tibiletti MG; Dirnhofer S; Tripodo C; Doglioni C; Dalla Favera R; Cavalli F; Zucca E; Kwee I; Bertoni F
Blood; 2011 Feb; 117(5):1595-604. PubMed ID: 21115979
[TBL] [Abstract][Full Text] [Related]
19. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
20. Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour.
Cozzi M; Marconato L; Martini V; Aresu L; Riondato F; Rossi F; Stefanello D; Comazzi S
Vet Comp Oncol; 2018 Jun; 16(2):246-252. PubMed ID: 29205839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
